Edwards Lifesciences Corp. (NYSE:EW) traded down 1.6% during mid-day trading on Friday . The stock traded as low as $104.92 and last traded at $105.27, with a volume of 1,636,493 shares traded. The stock had previously closed at $107.03.

Several equities research analysts have issued reports on the company. Piper Jaffray Cos. restated an “overweight” rating and set a $123.00 target price (up previously from $97.00) on shares of Edwards Lifesciences Corp. in a research report on Thursday, April 28th. Citigroup Inc. reaffirmed a “sell” rating and issued a $86.00 price target (up previously from $67.00) on shares of Edwards Lifesciences Corp. in a report on Wednesday, April 27th. Canaccord Genuity upped their price target on shares of Edwards Lifesciences Corp. from $113.00 to $123.00 and gave the stock a “buy” rating in a report on Wednesday, April 27th. BMO Capital Markets reaffirmed a “buy” rating on shares of Edwards Lifesciences Corp. in a report on Wednesday, April 27th. Finally, Morgan Stanley reaffirmed a “buy” rating on shares of Edwards Lifesciences Corp. in a report on Wednesday, April 27th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $106.14.

The firm’s 50-day moving average price is $100.77 and its 200 day moving average price is $93.45. The firm has a market capitalization of $22.29 billion and a price-to-earnings ratio of 44.81.

Edwards Lifesciences Corp. (NYSE:EW) last posted its earnings results on Tuesday, April 26th. The medical research company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business earned $697.30 million during the quarter, compared to the consensus estimate of $664.53 million. During the same quarter last year, the firm earned $1.12 earnings per share. The business’s quarterly revenue was up 18.1% on a year-over-year basis. On average, analysts expect that Edwards Lifesciences Corp. will post $2.76 EPS for the current fiscal year.

In other news, CEO Michael A. Mussallem sold 59,000 shares of the business’s stock in a transaction dated Friday, April 29th. The shares were sold at an average price of $106.13, for a total value of $6,261,670.00. Following the sale, the chief executive officer now directly owns 79,256 shares in the company, valued at approximately $8,411,439.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Huimin Wang sold 13,650 shares of the business’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $98.44, for a total transaction of $1,343,706.00. The disclosure for this sale can be found here.

A number of institutional investors have recently modified their holdings of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Edwards Lifesciences Corp. by 104.0% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,094 shares of the medical research company’s stock valued at $1,113,000 after buying an additional 7,186 shares during the last quarter. Navellier & Associates Inc increased its position in shares of Edwards Lifesciences Corp. by 82.2% in the fourth quarter. Navellier & Associates Inc now owns 17,295 shares of the medical research company’s stock valued at $1,366,000 after buying an additional 7,805 shares during the last quarter. Alpine Woods Capital Investors LLC increased its position in shares of Edwards Lifesciences Corp. by 67.1% in the fourth quarter. Alpine Woods Capital Investors LLC now owns 20,312 shares of the medical research company’s stock valued at $1,604,000 after buying an additional 8,156 shares during the last quarter. Andra AP fonden increased its position in shares of Edwards Lifesciences Corp. by 30.1% in the fourth quarter. Andra AP fonden now owns 39,800 shares of the medical research company’s stock valued at $3,143,000 after buying an additional 9,200 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its position in shares of Edwards Lifesciences Corp. by 320.0% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 13,038 shares of the medical research company’s stock valued at $1,030,000 after buying an additional 9,934 shares during the last quarter.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.